BRAF and colorectal carcinoma: There is a growing body of evidence reporting the rate of BRAF mutation in CRC patients, such as in Switzerland (19.7%) (28), Netherland (18.7%) (26), USA (21.8%) (27), Italy (14.9%) (29), France (4.3%) (30), and Belgium (4.7%) (31).